Respiratory syncytial virus infection in adult and paediatric patients admitted to intensive care in Australia A nationwide comparison with COVID19 summary

What is PACUPod: Critical Care?

PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across critical care and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.

Britany: Welcome back to PACULit. Today, we’re discussing a nationwide Australian study comparing respiratory syncytial virus (RSV) and COVID-19 in adult and pediatric ICU patients. Seth, RSV is increasingly recognized beyond infants.

Seth: Yes, RSV is a major cause of severe respiratory illness in infants but also affects adults, especially older adults with comorbidities. The pandemic highlighted viral respiratory infections, but direct ICU comparisons between RSV and COVID-19 have been limited until now.

Britany: The study by Tang et al. uses Australia’s ICU registry to address gaps about severity and mortality risk of RSV versus COVID-19 in adults and children admitted to intensive care.

Seth: Before this, large-scale data comparing these viruses head-to-head in critical care were lacking. Understanding mortality risk factors and resource use for RSV patients is crucial for ICU clinicians and healthcare systems.

Britany: The affected populations include older adults with chronic illnesses and frailty, plus pediatric patients, especially infants and those born prematurely or with underlying conditions.

Seth: The study was a retrospective cohort using the Australian ICU registry, including adults and children with lab-confirmed RSV or COVID-19. Patients without confirmed viral diagnoses or incomplete data were excluded, strengthening validity.

Britany: It was an observational comparison—no treatments tested. The primary outcome was ICU mortality; secondary outcomes included length of stay, mechanical ventilation, and organ support. Subgroup analyses considered age, comorbidities, and frailty.

Seth: Data spanned pre-pandemic, pandemic, and post-pandemic periods. They used descriptive statistics and multivariable logistic regression to identify mortality predictors, adjusting for confounders.

Britany: This robust approach allowed fair comparison of RSV and COVID-19 outcomes and identification of independent mortality risk factors.

Seth: Adult patients were older with multiple comorbidities and significant frailty. Pediatric patients were mostly infants, many premature or with underlying health issues.

Britany: This matches clinical knowledge—RSV severely affects young children, especially premature infants, who are disproportionately represented in ICUs.

Seth: A key finding was that ICU mortality for adults with RSV was comparable to COVID-19, challenging the view of RSV as mainly a pediatric concern and highlighting its severity in older adults.

Britany: Comorbidities and frailty drove mortality in RSV-infected adults, similar to COVID-19. This aligns with international studies identifying chronic conditions as predictors of poor outcomes.

Seth: Mechanical ventilation and organ support rates were similar between RSV and COVID-19 adults, showing comparable ICU burden.

Britany: In pediatrics, RSV accounted for more ICU admissions than COVID-19, with infants and premature babies at greatest risk. This aligns with US data showing higher ICU admission and ventilation rates in children with RSV.

Seth: Young age and prematurity were clear risk factors for severe pediatric disease, emphasizing the need for targeted prevention like RSV vaccination and prophylaxis in high-risk groups.

Britany: Although the study didn’t assess RSV vaccines directly, it highlights the urgent need for prospective studies on vaccination impact on ICU admissions and mortality.

Seth: The retrospective design and registry reliance pose limitations like potential misclassification and missing data, but the large, nationwide sample is a major strength.

Britany: Clinically, recognizing RSV as serious in adults with heart failure or hematologic malignancies is important, as these comorbidities increase risk.

Seth: Pharmacotherapy in adults with multiple comorbidities requires caution due to drug interactions, especially since no specific RSV antivirals are widely approved; supportive care remains key.

Britany: Clinicians must watch for polypharmacy and adverse effects, particularly in frail elderly patients.

Seth: The study also shows ICU teams should anticipate similar resource needs for RSV and COVID-19 patients, including ventilation and organ support, impacting staffing and equipment planning during respiratory virus seasons.

Britany: In pediatrics, the high RSV ICU burden calls for enhanced surveillance and early intervention, especially for premature infants or those with chronic lung disease.

Seth: Length of ICU stay was similar between RSV and COVID-19 groups, indicating RSV can cause prolonged critical illness, not just acute respiratory failure.

Britany: Prolonged ICU stays increase risks of secondary infections and post-ICU syndrome, areas needing further research for RSV survivors.

Seth: Clinically, this study encourages maintaining high suspicion for RSV in adults with severe respiratory symptoms during RSV season, not just focusing on COVID-19.

Britany: Diagnostic testing for RSV should be part of respiratory viral panels in ICUs to guide infection control and management.

Seth: From a healthcare perspective, recognizing RSV’s comparable ICU burden to COVID-19 supports allocating resources for RSV prevention and treatment research.

Britany: To summarize, this Australian study fills a critical gap by showing RSV causes severe respiratory illness requiring ICU care in adults and children, with mortality and resource use comparable to COVID-19.

Seth: It highlights comorbidities and frailty as key adult mortality factors and young age and prematurity as pediatric risk factors, informing clinical and public health strategies.

Britany: Thanks for the discussion, Seth. We recommend listeners review Tang et al.’s full study for more detail. Stay tuned for more PACULit updates.

Seth: Thanks, Britany. Looking forward to our next episode on emerging critical care therapies. Until then, keep up the great work managing these complex patients.

Britany: Take care, everyone!

Seth: Before we wrap up, Britany, it’s worth emphasizing how this study might influence future ICU protocols. For example, given the comparable severity of RSV and COVID-19 in adults, should we consider routine RSV screening during peak seasons in adult ICUs?

Britany: That’s a great point, Seth. Incorporating RSV testing could improve early diagnosis and isolation measures, reducing nosocomial transmission. Plus, it might help tailor supportive care more precisely, especially since treatment options differ from COVID-19.

Seth: Exactly. And with emerging RSV vaccines on the horizon, identifying high-risk patients early could facilitate timely immunization strategies, potentially reducing ICU admissions.

Britany: Speaking of vaccines, the study underscores the importance of including adults, particularly the elderly and those with comorbidities, in RSV vaccination programs once approved. Historically, RSV prevention has focused on infants, but this data suggests a broader approach is needed.

Seth: Absolutely. Another clinical implication is the need for heightened awareness among healthcare providers about RSV’s impact beyond pediatrics. This could improve patient counseling and encourage preventive measures like hand hygiene and avoiding exposure during outbreaks.

Britany: And from a research perspective, the study opens avenues to explore antiviral therapies for RSV in adults. Currently, options are limited, so clinical trials targeting this population are urgently needed.

Seth: I agree. Also, the similarity in ICU resource utilization between RSV and COVID-19 patients highlights the importance of pandemic preparedness plans that consider multiple respiratory pathogens, not just SARS-CoV-2.

Britany: That’s a critical takeaway. Hospitals should ensure adequate staffing, ventilators, and organ support equipment are available during respiratory virus seasons to manage surges effectively.

Seth: Lastly, the prolonged ICU stays seen with RSV raise questions about long-term outcomes. We need more data on post-ICU recovery and rehabilitation needs specific to RSV survivors.

Britany: Definitely. Understanding the trajectory of recovery can help optimize follow-up care and improve quality of life for these patients.

Seth: Well, Britany, this discussion really highlights how a single study can have wide-reaching implications for clinical practice, public health policy, and future research.

Britany: It does indeed. Thanks again for your insights, Seth. And thank you to our listeners for joining us on PACULit. Stay informed and stay safe!

Seth: Until next time!